Across the country, mothers and families have filed lawsuits against GlaxoSmithKline (“GSK”) over its alleged unlawful promotion of Zofran (ondansetron). The suits claim that after being prescribed the anti-nausea drug to treat morning sickness, mothers gave birth to children with birth defects including congenital heart defects and cleft palate, and that GSK marketed Zofran (ondansetron) “off label,” or for uses not approved by the FDA. Recently an Ohio mother filed suit, claiming that her son’s cleft palate was due to her taking Zofran (ondansetron) during her first trimester, causing him to endure eight surgeries.
With at least 55 lawsuits filed against GSK, plaintiffs are waiting to learn the outcome of the Judicial Panel on Multidistrict Litigation hearing held on October 1, 2015, where the panel met to decide whether or not the Zofran (ondansetron) cases will be centralized and consolidated into what is known as a multidistrict litigation, or MDL. An MDL coordinates cases alleging similar claims under one umbrella so that they may be heard by one judge, expediting discovery and reducing costs of pre-trial proceedings.
Law firm Grant & Eisenhofer filed the first case in the country and several more since then. If you or a loved one took Zofran (ondansetron) during your first trimester and your child was born with a congenital heart defect or cleft palate, call 877-978-0169 for a free, confidential legal consultation of your potential claim.